Company intelligence / Profile preview

Abzena

Ownership: Private
Development stage: Commercial

Overview

Abzena provides fully integrated services spanning drug discovery, development, process optimization, analytics/bioassays, cGMP manufacturing and scale-up for complex biologics and bioconjugates. It has supported over a hundred production cell lines and multiple INDs/clinical programs for partners. No direct clinical results as it operates as a service/CDMO partner.

Therapeutic areas: OncologyOther
Modalities: Biologics (including monoclonal antibodies)BioconjugatesAntibody-drug conjugates (ADCs)Protein therapeuticsCell line development
Industry: Drug Discovery Services

Partnerships

Numerous partnerships with pharmaceutical/biotech companies globally as a CDMO/CRO partner. Specific names are not disclosed publicly due to confidentiality agreements but the company highlights long-term collaborations across the industry.

Beyond the preview

Go deeper on Abzena.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Abzena.